Compare ADP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADP | SNY |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2B | 104.5B |
| IPO Year | 2005 | 2001 |
| Metric | ADP | SNY |
|---|---|---|
| Price | $283.02 | $45.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $275.57 | $58.00 |
| AVG Volume (30 Days) | 2.4M | ★ 3.0M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | 3.16% | ★ 3.47% |
| EPS Growth | ★ 9.62 | N/A |
| EPS | ★ 10.94 | N/A |
| Revenue | ★ $21,947,400,000.00 | N/A |
| Revenue This Year | $7.08 | $3.49 |
| Revenue Next Year | $5.69 | $6.10 |
| P/E Ratio | $25.87 | ★ $6.14 |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $188.16 | $40.89 |
| 52 Week High | $305.31 | $52.68 |
| Indicator | ADP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 62.69 |
| Support Level | $265.82 | $43.28 |
| Resistance Level | $280.59 | $48.66 |
| Average True Range (ATR) | 5.18 | 0.52 |
| MACD | -0.15 | 0.23 |
| Stochastic Oscillator | 72.94 | 87.91 |
Automatic Data Processing, or ADP, is a global, cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including PEO offerings, enabling clients to reduce HR overhead. Its broad suite serves customers of all sizes across diverse sectors, and the firm holds large market shares in its core markets. As of fiscal 2025, ADP counts over 1.1 million clients and manages payroll for more than 42 million workers across 140 countries.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.